Myalgic encephalomyelitis/chronic fatigue syndrome: A comprehensive review

Mateo Cortes Rivera*, Claudio Mastronardi, Claudia T. Silva-Aldana, Mauricio Arcos-Burgos, Brett A. Lidbury

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    138 Citations (Scopus)

    Abstract

    Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic disease of unknown aetiology that is recognized by the World Health Organization (WHO) and the United States Center for Disease Control and Prevention (US CDC) as a disorder of the brain. The disease predominantly affects adults, with a peak age of onset of between 20 and 45 years with a female to male ratio of 3:1. Although the clinical features of the disease have been well established within diagnostic criteria, the diagnosis of ME/CFS is still of exclusion, meaning that other medical conditions must be ruled out. The pathophysiological mechanisms are unclear but the neuro-immuno-endocrinological pattern of CFS patients gleaned from various studies indicates that these three pillars may be the key point to understand the complexity of the disease. At the moment, there are no specific pharmacological therapies to treat the disease, but several studies’ aims and therapeutic approaches have been described in order to benefit patients’ prognosis, symptomatology relief, and the recovery of pre-existing function. This review presents a pathophysiological approach to understanding the essential concepts of ME/CFS, with an emphasis on the population, clinical, and genetic concepts associated with ME/CFS.

    Original languageEnglish
    Article number91
    JournalDiagnostics
    Volume9
    Issue number3
    DOIs
    Publication statusPublished - 1 Sept 2019

    Fingerprint

    Dive into the research topics of 'Myalgic encephalomyelitis/chronic fatigue syndrome: A comprehensive review'. Together they form a unique fingerprint.

    Cite this